Gilead Sciences (GILD) 100.27 $GILD
Bristol-Myers Gets Priority Review for HCV Drug Daklinza
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 2:10PM CDT
Bristol-Myers Squibb (BMY) announced that three of its supplemental New Drug Applications seeking label expansion for hepatitis C drug, Daklinza, will be reviewed on a priority basis by the FDA.
GILD: 100.27 (+2.73), AZN: 31.92 (-0.16), ABBV: 55.63 (+0.55), BMY: 60.55 (+0.67)
BetterInvesting Top 100 Dropped 2.7% in September; 5-Year Increase Almost 14%
PR Newswire - Wed Oct 07, 11:31AM CDT
Through Sept. 30, the BetterInvesting Top 100 Index (BIXX), reflecting the portfolios of Main Street investors, increased by 13.5 percent annually for the previous five years, versus 13.8 percent for the Standard & Poor's 500 Equal-Weight Index (based on a total return for both indexes in which dividends are reinvested).
GILD: 100.27 (+2.73), DIS: 103.39 (-0.38), AAPL: 110.78 (-0.53)
Gilead (GILD) Stock: Looking at the Long Side
at The Street - Wed Oct 07, 10:33AM CDT
The technicals are good, and traders can look at the stock again from the long side.
GILD: 100.27 (+2.73)
Gilead: Improving Lives, Improving Stock
at The Street - Wed Oct 07, 10:03AM CDT
The technicals are good, and traders can look at the stock again from the long side.
GILD: 100.27 (+2.73)
Stock Market News for October 07, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 9:10AM CDT
Benchmarks finished mixed on Tuesday after a selloff in healthcare stocks offset gains in energy and materials shares
KMI: 32.14 (+0.36), BIIB: 279.24 (+3.25), MON: 88.06 (-0.02), AMGN: 148.05 (+6.83), XOM: 79.20 (+1.31), COP: 55.27 (+0.13), SLB: 75.35 (+1.41), CELG: 116.98 (+4.79), LYB: 95.59 (+1.96), GILD: 100.27 (+2.73), DD: 55.38 (+0.17), CVX: 88.12 (+1.13), DOW: 47.49 (+0.41), REGN: 485.76 (+25.94), ECL: 118.27 (+1.08)
Recession-Proofing Your Portfolio
at The Street - Wed Oct 07, 8:41AM CDT
The outlook on the U.S. economy is unclear, with recent data demonstrating too many contradictions: job growth remains weak, though consumer spending is strong.
GE: 27.77 (+0.48), DLTR: 62.90 (-2.29), GILD: 100.27 (+2.73), PFE: 33.29 (+0.50), MCD: 101.77 (-0.13), XOM: 79.20 (+1.31), DG: 67.45 (-1.27), CAT: 70.38 (-0.44), KORS: 42.72 (-0.65), MO: 55.90 (+0.49), PG: 73.72 (+0.32), INTC: 32.31 (+0.57)
Biotech's Bloodbath Is Ridiculous; Here's Why
George Budwell, The Motley Fool - Motley Fool - Wed Oct 07, 7:43AM CDT
Biotech has had an absolutely terrible time over the last few months, with most of the top dogs in the industry seeing their share prices get some pretty ugly haircuts: GILD data by YCharts . The odd and perhaps ridiculous part of...
GILD: 100.27 (+2.73), CELG: 116.98 (+4.79)
Here we go again: Earnings season begins with the 3rd consecutive quarter of negative expectations
ESTMZ - Wed Oct 07, 7:16AM CDT
Earnings season for the third quarter of 2015 unofficially kicks off on Thursday when Alcoa reports. Similar to the last two quarters, we head into the season with negative top and bottom-line growth expectations for the S&P 500… but as anyone...
BIIB: 279.24 (+3.25), F: 14.75 (+0.44), AA: 10.94 (-0.04), MON: 88.06 (-0.02), GILD: 100.27 (+2.73), FB: 92.40 (-0.40), STZ: 134.57 (+3.25), GM: 33.05 (+0.83), GOOGL: 670.00 (-1.64), HPQ: 28.01 (+0.01), SNDK: 61.69 (+0.45), YUM: 67.71 (-15.71), PEP: 98.52 (+1.45)
Drug Stocks' Earnings Power Won't Go Away
at The Street - Wed Oct 07, 4:23AM CDT
Before you sell them, ask yourself at what multiple you sell.
AGN: 268.99 (-3.89), JNJ: 94.98 (+1.56), ABT: 40.63 (+0.74), GILD: 100.27 (+2.73), AMGN: 148.05 (+6.83), RCPT: 231.96 (-0.03), TEVA: 58.55 (+0.58), REGN: 485.76 (+25.94), CELG: 116.98 (+4.79)
Global Indolent Lymphoma Pipeline Review, H2 2015 - 17 Companies & 25 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2nmbb/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Altor BioScience Corporation - Astellas Pharma Inc. - Bayer AG - Biothera, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Juno Therapeutics Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - MorphoSys AG Drug Profiles - acalisib - ALT-803 - bendamustine hydrochloride - BI-836826 - CC-122 - copanlisib hydrochloride - DI-B4 - duvelisib - entospletinib - ibrutinib - idelalisib - Imprime PGG - INCB-39110 - INCB-40093 - INCB-50465 - JCAR-015 - KTE-C19 - lenalidomide - MEDI-0680 - MEDI-551 - MEDI-551 MEDI-0680 - MOR-208 - obinutuzumab - venetoclax - vorinostat For more information visit http://www.researchandmarkets.com/research/q2...t_lymphoma
KITE: 64.57 (+1.60), GILD: 100.27 (+2.73), MRK: 50.95 (+1.15), INCY: 108.65 (-3.81), JUNO: 48.74 (+1.42), INFI: 7.79 (-0.24), ABBV: 55.63 (+0.55), CELGZ: 1.75 (+0.08)
Merck's (MRK) All-Oral Ribavirin-Free HCV Data Published
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 4:40PM CDT
Merck (MRK) announced that results from a phase III study on a chronic hepatitis C virus combination regimen of elbasvir and grazoprevir were published in The Lancet.
GILD: 100.27 (+2.73), MRK: 50.95 (+1.15), AMGN: 148.05 (+6.83), ABBV: 55.63 (+0.55)
Biotech stocks fall on trade deal and drug price scrutiny
By MARLEY JAY - AP - Tue Oct 06, 3:11PM CDT
NEW YORK (AP) — Biotech stocks slipped Tuesday on concerns about patent protection overseas and on continued scrutiny of the cost of some medications.
VRTX: 109.40 (-0.06), GILD: 100.27 (+2.73), AMGN: 148.05 (+6.83), REGN: 485.76 (+25.94), MS: 32.93 (+0.57), CELG: 116.98 (+4.79)
Why AbbVie Inc.'s Shares Slumped 13% in September
Todd Campbell, The Motley Fool - Motley Fool - Tue Oct 06, 12:00PM CDT
Amid a widespread industry sell-off, and in the wake of positive trial data from competitor Gilead Sciences , shares in AbbVie, Inc tumbled by 12.8% last month. AbbVie is under pressure to overcome looming headwinds tied to the...
GILD: 100.27 (+2.73), ABBV: 55.63 (+0.55)
Jim Cramer -- Peltz Will Be Great for GE, Amazon Can't Hurt Apple TV
at The Street - Tue Oct 06, 11:19AM CDT
On Tuesday, Jim Cramer discussed what's ahead for the stock market, why you should own General Electric, and why he's a fan of Columbia Sportswear.
BIIB: 279.24 (+3.25), AMZN: 541.94 (+4.46), GE: 27.77 (+0.48), VFC: 69.67 (-0.08), COLM: 57.77 (+0.57), XOM: 79.20 (+1.31), LULU: 54.00 (+2.26), PEP: 98.52 (+1.45), CELG: 116.98 (+4.79), JNJ: 94.98 (+1.56), AA: 10.94 (-0.04), GILD: 100.27 (+2.73), DD: 55.38 (+0.17), AAPL: 110.78 (-0.53)
Next Support Level for Gilead Sciences (GILD) is $95.77
Comtex SmarTrend(R) - Tue Oct 06, 9:34AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $99.41 today and has reached the first level of support at $97.51. Investors may be interested in a cross of the next downside pivot targets of $95.77 and $92.13.
GILD: 100.27 (+2.73)
3 Biotech Stocks That Have Been Unfairly Beaten Down
Brian Feroldi, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Tue Oct 06, 7:43AM CDT
Image by Gerald/Pixabay. What a brutal past few days it's been for biotech stocks. A simple tweet last week from presidential hopeful Hillary Clinton has caused biotech investors to get in a tizzy, and they've been selling off biotechs of all...
BLUE: 94.30 (-0.50), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56)
'Fast Money' Recap: Have Markets Risen Too Far Too Fast?
at The Street - Tue Oct 06, 4:00AM CDT
The trading panel discussed Dupont, Norman Peltz and if today's stock market is acting like 2011's.
SPY: 199.41 (+1.62), GILD: 100.27 (+2.73), DD: 55.38 (+0.17), IBB: 307.79 (+5.88), CELG: 116.98 (+4.79)
Gilead's Letairis Gets FDA Nod in Combination with Adcirca
Zacks Equity Research - Zacks Investment Research - Mon Oct 05, 4:00PM CDT
Gilead Sciences, Inc. (GILD) announced that the FDA has approved Letairis in combination with Eli Lilly and Company's (LLY) Adcirca for PAH.
GILD: 100.27 (+2.73), LLY: 83.99 (-0.18), GSK: 39.72 (-0.05), REGN: 485.76 (+25.94)
ContraVir Soars 150% as New HBV Drug is 60x More Active than Gilead's Viread
Andrew Steele - Zacks Investment Research - Mon Oct 05, 11:57AM CDT
ContraVir Pharmaceuticals announced earlier today that one of its drugs is more active than a drug produced by Gilead Sciences. Because of this, stock prices are up on the day.
CTRV: 3.17 (-0.82), GILD: 100.27 (+2.73)
3 Biotech Bargains to Buy
Todd Campbell, The Motley Fool - Motley Fool - Mon Oct 05, 7:02AM CDT
Biotechnology stocks are crashing, but not all biotech stocks are created equal. In fact, I think these three biotech stocks have something that every investor can get excited about: sales and profit growth. There's no telling where shares in ...
BIIB: 279.24 (+3.25), GILD: 100.27 (+2.73), CELG: 116.98 (+4.79)
Bristol-Myers Gets Priority Review for HCV Drug Daklinza
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 2:10PM CDT
Bristol-Myers Squibb (BMY) announced that three of its supplemental New Drug Applications seeking label expansion for hepatitis C drug, Daklinza, will be reviewed on a priority basis by the FDA.
GILD: 100.27 (+2.73), AZN: 31.92 (-0.16), ABBV: 55.63 (+0.55), BMY: 60.55 (+0.67)
BetterInvesting Top 100 Dropped 2.7% in September; 5-Year Increase Almost 14%
PR Newswire - Wed Oct 07, 11:31AM CDT
Through Sept. 30, the BetterInvesting Top 100 Index (BIXX), reflecting the portfolios of Main Street investors, increased by 13.5 percent annually for the previous five years, versus 13.8 percent for the Standard & Poor's 500 Equal-Weight Index (based on a total return for both indexes in which dividends are reinvested).
GILD: 100.27 (+2.73), DIS: 103.39 (-0.38), AAPL: 110.78 (-0.53)
Gilead (GILD) Stock: Looking at the Long Side
at The Street - Wed Oct 07, 10:33AM CDT
The technicals are good, and traders can look at the stock again from the long side.
GILD: 100.27 (+2.73)
Gilead: Improving Lives, Improving Stock
at The Street - Wed Oct 07, 10:03AM CDT
The technicals are good, and traders can look at the stock again from the long side.
GILD: 100.27 (+2.73)
Stock Market News for October 07, 2015
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 9:10AM CDT
Benchmarks finished mixed on Tuesday after a selloff in healthcare stocks offset gains in energy and materials shares
KMI: 32.14 (+0.36), BIIB: 279.24 (+3.25), MON: 88.06 (-0.02), AMGN: 148.05 (+6.83), XOM: 79.20 (+1.31), COP: 55.27 (+0.13), SLB: 75.35 (+1.41), CELG: 116.98 (+4.79), LYB: 95.59 (+1.96), GILD: 100.27 (+2.73), DD: 55.38 (+0.17), CVX: 88.12 (+1.13), DOW: 47.49 (+0.41), REGN: 485.76 (+25.94), ECL: 118.27 (+1.08)
Recession-Proofing Your Portfolio
at The Street - Wed Oct 07, 8:41AM CDT
The outlook on the U.S. economy is unclear, with recent data demonstrating too many contradictions: job growth remains weak, though consumer spending is strong.
GE: 27.77 (+0.48), DLTR: 62.90 (-2.29), GILD: 100.27 (+2.73), PFE: 33.29 (+0.50), MCD: 101.77 (-0.13), XOM: 79.20 (+1.31), DG: 67.45 (-1.27), CAT: 70.38 (-0.44), KORS: 42.72 (-0.65), MO: 55.90 (+0.49), PG: 73.72 (+0.32), INTC: 32.31 (+0.57)
Biotech's Bloodbath Is Ridiculous; Here's Why
George Budwell, The Motley Fool - Motley Fool - Wed Oct 07, 7:43AM CDT
Biotech has had an absolutely terrible time over the last few months, with most of the top dogs in the industry seeing their share prices get some pretty ugly haircuts: GILD data by YCharts . The odd and perhaps ridiculous part of...
GILD: 100.27 (+2.73), CELG: 116.98 (+4.79)
Here we go again: Earnings season begins with the 3rd consecutive quarter of negative expectations
ESTMZ - Wed Oct 07, 7:16AM CDT
Earnings season for the third quarter of 2015 unofficially kicks off on Thursday when Alcoa reports. Similar to the last two quarters, we head into the season with negative top and bottom-line growth expectations for the S&P 500… but as anyone...
BIIB: 279.24 (+3.25), F: 14.75 (+0.44), AA: 10.94 (-0.04), MON: 88.06 (-0.02), GILD: 100.27 (+2.73), FB: 92.40 (-0.40), STZ: 134.57 (+3.25), GM: 33.05 (+0.83), GOOGL: 670.00 (-1.64), HPQ: 28.01 (+0.01), SNDK: 61.69 (+0.45), YUM: 67.71 (-15.71), PEP: 98.52 (+1.45)
Drug Stocks' Earnings Power Won't Go Away
at The Street - Wed Oct 07, 4:23AM CDT
Before you sell them, ask yourself at what multiple you sell.
AGN: 268.99 (-3.89), JNJ: 94.98 (+1.56), ABT: 40.63 (+0.74), GILD: 100.27 (+2.73), AMGN: 148.05 (+6.83), RCPT: 231.96 (-0.03), TEVA: 58.55 (+0.58), REGN: 485.76 (+25.94), CELG: 116.98 (+4.79)
Global Indolent Lymphoma Pipeline Review, H2 2015 - 17 Companies & 25 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2nmbb/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Altor BioScience Corporation - Astellas Pharma Inc. - Bayer AG - Biothera, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Juno Therapeutics Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - MorphoSys AG Drug Profiles - acalisib - ALT-803 - bendamustine hydrochloride - BI-836826 - CC-122 - copanlisib hydrochloride - DI-B4 - duvelisib - entospletinib - ibrutinib - idelalisib - Imprime PGG - INCB-39110 - INCB-40093 - INCB-50465 - JCAR-015 - KTE-C19 - lenalidomide - MEDI-0680 - MEDI-551 - MEDI-551 MEDI-0680 - MOR-208 - obinutuzumab - venetoclax - vorinostat For more information visit http://www.researchandmarkets.com/research/q2...t_lymphoma
KITE: 64.57 (+1.60), GILD: 100.27 (+2.73), MRK: 50.95 (+1.15), INCY: 108.65 (-3.81), JUNO: 48.74 (+1.42), INFI: 7.79 (-0.24), ABBV: 55.63 (+0.55), CELGZ: 1.75 (+0.08)
Merck's (MRK) All-Oral Ribavirin-Free HCV Data Published
Zacks Equity Research - Zacks Investment Research - Tue Oct 06, 4:40PM CDT
Merck (MRK) announced that results from a phase III study on a chronic hepatitis C virus combination regimen of elbasvir and grazoprevir were published in The Lancet.
GILD: 100.27 (+2.73), MRK: 50.95 (+1.15), AMGN: 148.05 (+6.83), ABBV: 55.63 (+0.55)
Biotech stocks fall on trade deal and drug price scrutiny
By MARLEY JAY - AP - Tue Oct 06, 3:11PM CDT
NEW YORK (AP) — Biotech stocks slipped Tuesday on concerns about patent protection overseas and on continued scrutiny of the cost of some medications.
VRTX: 109.40 (-0.06), GILD: 100.27 (+2.73), AMGN: 148.05 (+6.83), REGN: 485.76 (+25.94), MS: 32.93 (+0.57), CELG: 116.98 (+4.79)
Why AbbVie Inc.'s Shares Slumped 13% in September
Todd Campbell, The Motley Fool - Motley Fool - Tue Oct 06, 12:00PM CDT
Amid a widespread industry sell-off, and in the wake of positive trial data from competitor Gilead Sciences , shares in AbbVie, Inc tumbled by 12.8% last month. AbbVie is under pressure to overcome looming headwinds tied to the...
GILD: 100.27 (+2.73), ABBV: 55.63 (+0.55)
Jim Cramer -- Peltz Will Be Great for GE, Amazon Can't Hurt Apple TV
at The Street - Tue Oct 06, 11:19AM CDT
On Tuesday, Jim Cramer discussed what's ahead for the stock market, why you should own General Electric, and why he's a fan of Columbia Sportswear.
BIIB: 279.24 (+3.25), AMZN: 541.94 (+4.46), GE: 27.77 (+0.48), VFC: 69.67 (-0.08), COLM: 57.77 (+0.57), XOM: 79.20 (+1.31), LULU: 54.00 (+2.26), PEP: 98.52 (+1.45), CELG: 116.98 (+4.79), JNJ: 94.98 (+1.56), AA: 10.94 (-0.04), GILD: 100.27 (+2.73), DD: 55.38 (+0.17), AAPL: 110.78 (-0.53)
Next Support Level for Gilead Sciences (GILD) is $95.77
Comtex SmarTrend(R) - Tue Oct 06, 9:34AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bearishly below the pivot of $99.41 today and has reached the first level of support at $97.51. Investors may be interested in a cross of the next downside pivot targets of $95.77 and $92.13.
GILD: 100.27 (+2.73)
3 Biotech Stocks That Have Been Unfairly Beaten Down
Brian Feroldi, Sean Williams, and Cheryl Swanson, The Motley Fool - Motley Fool - Tue Oct 06, 7:43AM CDT
Image by Gerald/Pixabay. What a brutal past few days it's been for biotech stocks. A simple tweet last week from presidential hopeful Hillary Clinton has caused biotech investors to get in a tizzy, and they've been selling off biotechs of all...
BLUE: 94.30 (-0.50), GILD: 100.27 (+2.73), HZNP: 18.35 (-0.56)
'Fast Money' Recap: Have Markets Risen Too Far Too Fast?
at The Street - Tue Oct 06, 4:00AM CDT
The trading panel discussed Dupont, Norman Peltz and if today's stock market is acting like 2011's.
SPY: 199.41 (+1.62), GILD: 100.27 (+2.73), DD: 55.38 (+0.17), IBB: 307.79 (+5.88), CELG: 116.98 (+4.79)
Gilead's Letairis Gets FDA Nod in Combination with Adcirca
Zacks Equity Research - Zacks Investment Research - Mon Oct 05, 4:00PM CDT
Gilead Sciences, Inc. (GILD) announced that the FDA has approved Letairis in combination with Eli Lilly and Company's (LLY) Adcirca for PAH.
GILD: 100.27 (+2.73), LLY: 83.99 (-0.18), GSK: 39.72 (-0.05), REGN: 485.76 (+25.94)
ContraVir Soars 150% as New HBV Drug is 60x More Active than Gilead's Viread
Andrew Steele - Zacks Investment Research - Mon Oct 05, 11:57AM CDT
ContraVir Pharmaceuticals announced earlier today that one of its drugs is more active than a drug produced by Gilead Sciences. Because of this, stock prices are up on the day.
CTRV: 3.17 (-0.82), GILD: 100.27 (+2.73)
3 Biotech Bargains to Buy
Todd Campbell, The Motley Fool - Motley Fool - Mon Oct 05, 7:02AM CDT
Biotechnology stocks are crashing, but not all biotech stocks are created equal. In fact, I think these three biotech stocks have something that every investor can get excited about: sales and profit growth. There's no telling where shares in ...
BIIB: 279.24 (+3.25), GILD: 100.27 (+2.73), CELG: 116.98 (+4.79)
